For example, the CBP/p300 inhibitor CPI-0610 shows promise in preclinical models of pancreatic cancer by disrupting the lactylation-TTK/BUB1B feedback loop, while HDAC1 agonist entinostat reverses immunosuppression in colorectal cancer by de-repressing CD8+ T cell infiltration. Here, EP300 is linked to colorectal cancer.